Matthew Ho
- Organic Chemistry top 5%
- Hematology top 5%
- Multiple Myeloma Research and Treatments 20
- Cancer Research top 10%
- MicroRNA in disease regulation 3
- Oncology top 10%
- Peptidase Inhibition and Analysis 5
- Pharmaceutical Science top 5%
-
- Protein Degradation and Inhibitors 17
- Ubiquitin and proteasome pathways 7
- Extracellular vesicles in disease 3
-
- Immunotherapy and Immune Responses 3
-
- Monoclonal and Polyclonal Antibodies Research 2
- Co-authors
- Florian BergerWanwan YuNils FrankTobias RitterMatthew B. PlutschackAmanda McCannGiada BianchiLuke Gubbins
- Partner nations
- United StatesIrelandChina
In The Last Decade
Matthew Ho
36 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 109
- Organic Chemistry 541
- Hematology 206
- Cancer Research 210
- Oncology 322
- Pharmaceutical Science 67
Countries citing papers authored by Matthew Ho
This map shows the geographic impact of Matthew Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Ho more than expected).
Fields of papers citing papers by Matthew Ho
This network shows the impact of papers produced by Matthew Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Ho. The network helps show where Matthew Ho may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Matthew Ho, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 4 | |
| 5 | 2023 | 10 | |
| 6 | 2021 | 6 | |
| 7 | 2021 | 12 | |
| 8 | 2021 | 4 | |
| 9 | 2021 | 9 | |
| 10 | 2020 | 45 | |
| 11 | 2020 | 28 | |
| 12 | 2020 | 10 | |
| 13 | 2020 | 52 | |
| 14 | 2018 | 65 | |
| 15 | 2017 | 2 | |
| 16 | Targeting Protein Synthesis and Degradation in Multiple Myeloma: A Look at What’s on the Horizon | 2017 | 4 |
| 17 | 2017 | 10 | |
| 18 | 2017 | 29 | |
| 19 | 2016 | 1 | |
| 20 | 2015 | 306 |
About Matthew Ho
Matthew Ho is a scholar working on Hematology, Oncology and Molecular Biology, having authored 39 papers that have together received 1.5k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (20 papers), Protein Degradation and Inhibitors (17 papers), Ubiquitin and proteasome pathways (7 papers), Peptidase Inhibition and Analysis (5 papers), MicroRNA in disease regulation (3 papers), Immunotherapy and Immune Responses (3 papers), Extracellular vesicles in disease (3 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Organic Chemistry (541 citations), Hematology (206 citations) and Cancer Research (210 citations). Matthew Ho has collaborated with scholars based in United States, Ireland and China. Frequent co-authors include Florian Berger, Wanwan Yu, Nils Frank, Tobias Ritter, Matthew B. Plutschack, Amanda McCann, Giada Bianchi, Luke Gubbins, Karolina Weiner‐Gorzel and Kenneth C. Anderson. Their work appears in journals such as Blood, Leukemia, Blood Cancer Journal, Journal of Clinical Oncology and Tetrahedron.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.